HCAR2 Antikörper (AA 250-350)

Produktnummer ABIN7267804

Produktdetails anti-HCAR2 Antikörper

Target: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Bindungsspezifität: AA 250-350

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HCAR2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)

Verwendungszweck: HCAR2 Rabbit pAb

Sequenz: VRIRIFWLLH TSGTQNCEVY RSVDLAFFIT LSFTYMNSML DPVVYYFSSP SFPNFFSTLI NRCLQRKMTG EPDNNRSTSV ELTGDPNKTR GAPEALMANS G

Kreuzreaktivität: Human, Maus, Ratte

Produktmerkmale: Polyclonal Antibodies

Aufreinigung: Affinity purification

Immunogen: A synthetic peptide corresponding to a sequence within amino acids 250-350 of human HCAR2 (NP_808219.1).

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB,1:500 - 1:2000,IHC,1:50 - 1:200,IF,1:50 - 1:200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Avoid freeze / thaw cycles.

Details zu HCAR2

Target: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Andere Bezeichnung: HCAR2 (HCAR2 Produkte)

Synonyme: GPR109A antikoerper, HCA2 antikoerper, HM74a antikoerper, HM74b antikoerper, NIACR1 antikoerper, PUMAG antikoerper, Puma-g antikoerper, Gpr109a antikoerper, Gpr109b antikoerper, HM74 antikoerper, Hcar2 antikoerper, PUMA-G antikoerper, Pumag antikoerper, mHM74b antikoerper, HCAR2 antikoerper, HCAR3 antikoerper, hydroxycarboxylic acid receptor 2 antikoerper, HCAR2 antikoerper, Hcar2 antikoerper, LOC527744 antikoerper

Hintergrund: Acts as a high affinity receptor for both nicotinic acid (also known as niacin and (D-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.,HCAR2,GPR109A,HCA2,HM74a,HM74b,NIACR1,PUMAG,Puma-g,Cancer,Tumor suppressors,p53 pathway,Signal Transduction,G protein signaling,G-Protein-Coupled Receptors(GPCR),Cell Biology & Developmental Biology,Apoptosis,Endocrine & Metabolism,Lipid Metabolism,Hydrolysis,Cardiovascular,Lipids,HCAR2

Molekulargewicht: 42kDa

Gen-ID: 338442

UniProt: Q8TDS4